2026 Volume 73 Issue 3.4 Pages 566-568
Introduction:Clozapine is the gold standard treatment for treatment-resistant schizophrenia;however, discontinuation may be necessary because of hematologic side effects such as neutropenia. This report describes a case in which clozapine was reintroduced along with lithium after neutropenia, resulting in a favorable outcome. Case Presentation:A 31-year-old woman with a 16-year history of schizophrenia remained stable on clozapine (300 mg/day) after failing to respond to multiple antipsychotics. However, clozapine was discontinued when neutropenia (absolute neutrophil count, 1,414/μL) developed during viral-like symptoms. Subsequently, her psychiatric symptoms recurred, and other medications were ineffective. Therefore, clozapine was reinitiated in combination with lithium. Hematologic abnormalities did not recur, and behavioral symptoms improved markedly. After increasing the dose of clozapine to 450 mg/day and that of lithium to 800 mg/day, she experienced a generalized tonic–clonic seizure. However, after reducing the dose of these medications, no recurrence occurred, and her condition remained stable. Conclusion:Based on the revised Japanese clozapine monitoring guidelines, the reintroduction of clozapine after viral neutropenia is possible through multidisciplinary collaboration. Lithium co-administration may have contributed to hematologic stability by promoting granulocyte production. However, caution is warranted because of the increased seizure risk, and careful monitoring of neurological side effects is essential. J. Med. Invest. 73 : 566-568, August, 2026